Quality of life (QoL) in SAKK 19/03: A multicenter phase II study of first-line gefitinib followed by chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Swiss Group for Clinical Cancer Research (SAKK)

G. D’Addario(Kantonsspital St. Gallen), Daniel Betticher, Daniel Rauch(Washington University in St. Louis), Miklos Pless(Ontario Institute for Cancer Research), Roger Stupp(Northwestern University), Kaspar Rufibach(Kantonsspital St. Gallen), Stefanie Lerch(Swiss Group For Clinical Cancer Research), Florian Strasser(University of St.Gallen), R. Stahel, Karin Ribi
Journal of Clinical Oncology
June 20, 2006
10.1200/jco.2006.24.18_suppl.18559
Cited by 0

Related Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
ESPEN guidelines on nutrition in cancer patients
|Clinical Nutrition|2016|3k
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
|JAMA|2017|2.5k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k